NCT02107274View on ClinicalTrials.gov

Efficacy of Azithromycin in Treatment of Bronchiectasis

PHASE4CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Bronchiectasis
Interventions
DRUG

Azithromycin

Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics

DRUG

Placebo for Azithromycin

In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.

Trial Locations (1)

34000

Respiratory Unit, Taiping Hospital, Taiping

All Listed Sponsors
lead

Penang Hospital, Malaysia

OTHER_GOV

NCT02107274 - Efficacy of Azithromycin in Treatment of Bronchiectasis | Biotech Hunter | Biotech Hunter